A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma.
D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology*; D018572:Disease-Free Survival; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D020778:Matrix Metalloproteinase 2 / Q000096:biosynthesis*; D020780:Matrix Metalloproteinase 9 / Q000096:biosynthesis*; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D016016:Proportional Hazards Models; D013629:Tamoxifen / Q000494:pharmacology; D013997:Time Factors; D017312:Toremifene / Q000494:pharmacology; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D017312:Toremifene; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9